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Stem Cell Transplantation
Reduced-intensity allogeneic stem cell transplantation
for renal cell carcinoma: in vivo evidence of a 
graft-versus-tumor effect
We report the cases of 3 patients with advanced renal
cell carcinoma who underwent reduced-intensity allo-
geneic stem cell transplantation. In 2 partial responders,
histologic analyses of metastases revealed prominent
accumulation of CD8+ T cells and degenerative changes of
clear cell carcinoma, suggestive of induction of tumor-
specific cytotoxic T lymphocytes.haematologica 2004; 89:375-376
(http://www.haematologica.org/2004/3/375)
Recently, reduced-intensity allogeneic stem cell trans-
plantation (RIST) has been introduced into the treatment of
renal cell carcinoma (RCC).1-5 We report the preliminary
results of RIST in 3 patients (Table 1) with advanced RCC
refractory to cytokine-based therapy, and show the histo-
logic analyses before and after transplantation. The patients
and donors gave written informed consent to participate in
this institutionally approved investigational protocol. The
preparative regimen, consisting of cyclophosphamide and
fludarabine,  was entirely based on a previously reported
study and included cyclosporine (CSP).1 Patients received
granulocyte colony-stimulating factor-mobilized peripher-
al blood stem cells from their HLA-identical siblings on day
0.  Following transplantation, the degree of donor-recipient
chimerism in both myeloid and T-cell lineages was assessed
by polymerase-chain reaction assay according to a pub-
lished method.1
All three patients achieved sustained myeloid and platelet
engraftment with the proportion of donor cells in the
peripheral blood exceeding 80% for both T cells and gran-
ulocytes within 2 months. We observed 2 partial responses
in patients #1 and #3 six months and eight months after
transplantation respectively: one response occurred after
the development of chronic graft-versus-host disease
(GVHD) and the other after acute GVHD: both coincided
with full donor T-cell chimerism.  Thereafter, the disease in
patient #1 remained stable while GVHD responded to treat-
ment with low-dose CSP plus steroids.  Unfortunately, this
patient died of bacterial pneumonia on day 554. In patient
#3, chronic GVHD of the skin, salivary glands, and lung
required treatment with CSP and steroids.  Twenty months
after transplantation, metastases started to grow despite a
lack of change in GVHD.  Reducing CSP and steroids caused
acute respiratory failure due to chronic lung GVHD, though
some regression of RCC metastases was observed. This
Table 1. Characteristics of the patients and outcome of transplantation.
Patient Age Histology Sites of No. of Nephrectomy Age CD34+ cells No. of GVHD Response Outcome
no. (yr)/sex metastases previous (yr)/sex kg infused CD3+ cells/kg
systemic of donor (×106) infused 
treatments (×108)
1 64/M Clear cell Lung, 3 Yes 69/M 5.6 3.0 Extensive PR SD; died of
pleura, bone, chronic skin, pneumonia
nodes oral, salivary on day
554
2 58/F Papillary Pleura, liver, 2 No 59/M 9.7 4.3 Acute grade 3 PD Died of
adrenal, nodes skin, liver, GI disease
progression
on day 68
3 56/M Clear cell Bone, lung, 3 Yes 51/F 4.9 2.4 Acute grade 2 PR Died of
pleura, adrenal, skin, GI, progressive
nodes extensive chronic skin, and GVHD 
disease salivary, lung on day 709
M: male; F: female; GVHD: graft-versus-host disease; GI: gastrointestinal; PR: partial response; SD: stable disease; PD: progressive disease.
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patient died of respiratory failure from GVHD and disease
progression on day 709. Since the median survival of
patients with cytokine therapy-resistant metastatic RCC is
less than 6 months,6 having stabilized disease progression
for 12 months in patient #3 may be noteworthy. Patient #2
progressed soon after the transplantation and did not
respond to withdrawal of CSP on day 18. To induce a graft-
versus-tumor (GVT) effect, she received interleukin-2 plus
donor-lymphocyte infusion with 3.0×108 CD3+ cells/kg on
day 27. On day 45, grade III GVHD of the liver and intestine
developed. Shortly thereafter lymphadenopathy in the neck
and axilla regressed gradually, but there was no reduction
in massive pleural effusions.  Patient #2 died of disease pro-
gression on day 68.
Histologic analyses of the pleural metastasis in patient #1
revealed intact tumor cell architecture and the absence of
lymphocyte infiltration before transplantation (Figure 1A).
However, after transplantation we found an accumulation
of mononuclear cells corresponding to a degenerative lesion
of clear cell carcinoma (Figure 1B), which mainly consisted
of CD3+CD8+ cells (Figure 1C), but not CD4+ cells (Figure 1D).
The other metastases in lung, bone, and lymph nodes also
showed considerable penetration by infiltrating CD8+ cells.
These findings were also seen in patient #3. Post-mortem
sections of bone, lung, pleura, adrenal, and lymph node
metastases were found to contain abundant infiltrating
CD8+ cells.  In patient #2, conversely, lymphocyte infiltra-
tion and destruction of tumor were not present in metasta-
tic sites examined post-mortem, except for a small number
of lymphocytes seen in the supraclavicular lymph node and
the primary lesion of the left kidney as well as minimal
destruction of the primary tumor.
Our study showed that the GVT effect was closely asso-
ciated with infiltration of CD8+ cells without infiltration of
CD4+ cells, although there is a possibility that T cells seen
after death may differ from those at the time of response. 
These findings suggest that the GVT effect after RIST may
be mediated by induction of tumor-specific cytotoxic T lym-
phocytes (CTL) rather than induction of lymphocytes which
secrete cytokines locally, since cytokine secretion and cyto-
toxicity are mainly functions of CD4+ cells and CD8+, cells
respectively. The future direction of this study will be to iso-
late tumor antigens exclusively or preferentially presented
by tumor cells, and generation of CTL specific for these
tumor antigens.
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Figure 1. Photomicrographs of pleural metastases of RCC
from patient #1. (A) Before transplantation, the clear cell
architecture was intact in a pleural section obtained by
open-lung biopsy.  (B) In the pleural section taken post-
mortem, tumor cell detritus and heavy mononuclear cell
infiltration were seen.  Immunohistochemical staining
with monoclonal antibodies against CD8 (C) and CD4 (D)
antigens showed that mononuclear cells in the post-
mortem pleural section were primarily CD8+. Original
magnification, ×¥200. 
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